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Insulin-like growth factor binding proteins (IGFBPs) bind to and modulate the actions 
of insulin-like growth factors (IGFs)1. Although some of the actions of IGFBPs have 
been reported to be independent of IGFs, the precise mechanisms of IGF-independent 
actions of IGFBPs are largely unknown1,2. Here we report a previously unknown 
function for IGFBP-4 as a cardiogenic growth factor. IGFBP-4 enhanced 
cardiomyocyte differentiation in vitro, and knockdown of IGFBP-4 attenuated 
cardiomyogenesis both in vitro and in vivo. The cardiogenic effect of IGFBP-4 was 
independent of its IGF binding activity but was mediated by the inhibitory effect on 
canonical Wnt signaling. IGFBP-4 physically interacted with a Wnt receptor Frizzled 8 
(Frz8) and a Wnt co-receptor low-density lipoprotein receptor-related protein 6 (LRP6), 
and inhibited Wnt3A binding to Frz8 and LRP6. Although IGF-independent, the 
cardiogenic effect of IGFBP-4 was attenuated by IGFs through IGFBP-4 sequestration. 
Thus, IGFBP-4 is an inhibitor of canonical Wnt signaling required for cardiogenesis, 
and provides a molecular link between IGF signaling and Wnt signaling. 
The heart is the first organ to form during embryogenesis, and abnormalities in this 
process result in congenital heart diseases, the most common cause of birth defects in 
humans3,4. Molecules that mediate cardiogenesis are of particular interest because of their 
potential use for cardiac regeneration5,6. Previous studies have shown that soluble growth 
factors such as bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), 
Wnts, and Wnt inhibitors mediate the tissue interactions critical for cardiomyocyte 
specification4,6. We hypothesized that there might be additional soluble factors that 
modulate cardiac development and/or cardiomyocyte differentiation. 
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P19CL6 cells differentiate into cardiomyocytes with high efficiency in the presence of 
1% DMSO7. We cultured P19CL6 cells with culture media conditioned by various cell 
types in the absence of DMSO and screened the cardiogenic activity of the conditioned 
media. The extent of cardiomyocyte differentiation was assessed by the immunostaining 
with MF20 monoclonal antibody that recognizes sarcomeric myosin heavy chain (MHC). 
Among the several cell types tested, culture media conditioned by a murine stromal cell 
line OP9 induced cardiomyocyte differentiation of P19CL6 cells without DMSO treatment 
(Fig. 1a, left and middle panels). Increased MF20-positive area was accompanied by the 
induction of cardiac marker genes such as ?MHC, Nkx2.5, and GATA-4, and by the 
increased protein levels of cardiac troponin T (cTnT) (Fig. 1a, right panel). In contrast, 
culture media conditioned by COS7 cells, mouse embryonic fibroblasts, NIH3T3 cells, 
HeLa cells, END2 cells (visceral endoderm-like cells), neonatal rat cardiomyocytes, and 
neonatal rat cardiac fibroblasts did not induce cardiomyocyte differentiation of P19CL6 
cells in the absence of DMSO (Fig. 1a and data not shown). From these observations, we 
postulated that OP9 cells secrete a cardiogenic growth factor(s). 
To identify an OP9-derived cardiogenic factor, cDNA clones isolated by a signal 
sequence trap method from an OP9 cell cDNA library8 were tested for their cardiogenic 
activities by transient transfection. When available, recombinant proteins were also used to 
confirm the results. Among candidate factors tested, IGFBP-4 induced cardiomyocyte 
differentiation of P19CL6 cells as evidenced by the increase in MF20-positive area and the 
induction of cardiac markers (Fig. 1b). We also cultured P19CL6 cells with OP9-
conditioned media pretreated with an anti-IGFBP-4 neutralizing antibody. The application 
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of an anti-IGFBP-4 neutralizing antibody attenuated the efficiency of cardiomyocyte 
differentiation induced by OP9-conditioned media (Fig. 1c). These findings strongly 
suggest that IGFBP-4 is a cardiogenic factor secreted from OP9 cells.  
Since IGFBPs have been characterized as molecules that bind to and modulate the 
actions of IGFs, we tested whether IGFBP-4 promotes cardiogenesis by either enhancing or 
inhibiting the actions of IGFs. We first treated P19CL6 cells with a combination of anti-
IGF-I and IGF-II neutralizing antibodies or a neutralizing antibody against type-I IGF 
receptor. If IGFBP-4 induces cardiomyocyte differentiation by inhibiting IGF signaling, 
treatment with these antibodies should induce cardiomyocyte differentiation and/or enhance 
the cardiogenic effects of IGFBP-4. On the other hand, if IGFBP-4 promotes cardiogenesis 
by enhancing IGF signaling, treatment with these antibodies should attenuate IGFBP-4-
mediated cardiogenesis. However, treatment with these antibodies did not affect the 
efficiency of IGFBP-4-induced cardiomyocyte differentiation (Fig. 1d and data not shown). 
Treatment of P19CL6 cells with IGF-I and –II also did not induce cardiomyocyte 
differentiation (data not shown). Furthermore, treatment with an IGFBP-4 mutant (IGFBP-
4-H74P; His74 replaced by Pro)9 that is unable to bind IGFs induced cardiomyocyte 
differentiation of P19CL6 cells even more efficiently than wild type IGFBP-4 (Fig. 1e). 
This is presumably due to the sequestration of wild type IGFBP-4 but not mutant IGFBP-4-
H74P by endogenous IGFs. Consistent with this idea, exogenous IGFs attenuated wild type 
IGFBP-4- but not IGFBP-4-H74P-induced cardiogenesis (Fig. 1f). Taken together, these 
observations indicate that IGFBP-4 induces cardiomyocyte differentiation in an IGF-
independent fashion. 
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In order to further explore the mechanisms by which IGFBP-4 induces 
cardiomyogenesis, we tested the hypothesis that IGFBP-4 might modulate the signals 
activated by other secreted factors implicated in cardiogenesis. It has been shown that 
canonical Wnt signaling plays a critical role in cardiomyocyte differentiation4,6. In P19CL6 
cells, Wnt3A treatment activated ?-catenin-dependent transcription of TOPFLASH reporter 
gene, and this activation was attenuated by IGFBP-4 (Fig. 2a). Wnt/?-catenin signaling is 
transduced by the cell surface receptor complex consisting of Frizzled and low density 
lipoprotein receptor (LDLR)-related protein 5/6 (LRP5/6)10,11, and IGFBP-4 attenuated 
TOPFLASH activity enhanced by the expression of LRP6 or Frizzled 8 (Frz8) (Fig. 2a). As 
a control, IGFBP-4 did not alter BMP-mediated activation of a BMP-responsive reporter 
BRE-luc (Supplementary Fig. S1b). These findings suggest that IGFBP-4 is a specific 
inhibitor of canonical Wnt pathway. To examine this notion in vivo, we performed axis 
duplication assays in Xenopus embryos. Injection of Xwnt8 or LRP6 mRNA caused 
secondary axis formation, and injection of Xenopus IGFBP-4 (XIGFBP-4) mRNA alone 
had minimal effects on axis formation. However, Xwnt8- or LRP6-induced secondary axis 
formation was efficiently blocked by co-expression of XIGFBP-4 (Fig. 2b,c), indicating 
that IGFBP-4 inhibits canonical Wnt signaling in vivo. To explore the mechanisms of Wnt 
inhibition by IGFBP-4, Xenopus animal cap assays and TOPFLASH reporter gene assays 
were performed. In animal cap assays, IGFBP-4 inhibited LRP6-induced but not ?-catenin-
induced Wnt target gene expression (Supplementary Fig. S1c). Likewise, IGFBP-4 
attenuated Wnt3A- or LRP6-induced TOPFLASH activity but did not alter Dishevelled-1?
(Dvl-1)-, LiCl-, or ?-catenin-induced TOPFLASH activity (Supplementary Fig. S1d,e). 
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These findings suggest that IGFBP-4 inhibits canonical Wnt signaling at the level of cell 
surface receptors. To examine whether IGFBP-4 antagonizes Wnt signaling via direct 
physical interaction with LRP5/6 or Frizzled, we produced conditioned media containing 
Myc-tagged extracellular portion of LRP6 (LRP6N-Myc), Myc-tagged cysteine-rich 
domain (CRD) of Frz8 (Frz8CRD-Myc), and V5-tagged IGFBP-4 (IGFBP-4-V5). 
Immunoprecipitation (IP)/Western experiments revealed that IGFBP-4 interacted with 
LRP6N (Fig. 2d) and Frz8CRD (Fig. 2e). A liquid-phase binding assay using 125I-labeled 
IGFBP-4 and conditioned media containing LRP6N-Myc or Frz8CRD-Myc demonstrated 
that the interaction between IGFBP-4 and LRP6N or Frz8CRD was specific and saturable 
(Fig. 2f,g). Scatchard plot analysis revealed two binding sites with different binding 
affinities for LRP6N (Fig. 2f, inset) and a single binding site for Frz8CRD (Fig. 2g, inset). 
A similar binding assay using 125I-labeled Wnt3A demonstrated that IGFBP-4 inhibited 
Wnt3A binding to LRP6N (Fig. 2h) and Frz8CRD (Fig. 2i), and Lineweaver-Burk plot 
revealed that IGFBP-4 was a competitive inhibitor of Wnt3A binding to Frz8CDR 
(Supplementary Fig. S2a). IP/Western analyses using various deletion mutants of LRP6 and 
IGFBP-4 revealed that IGFBP-4 interacted with multiple domains of LRP6, and that the 
carboxy-terminal thyroglobulin domain of IGFBP-4 was required for IGFBP-4 binding to 
LRP6 or Frz8CRD (Supplementary Fig. S2b-f). It has been shown that inhibition of 
canonical Wnt signaling promotes cardiomyocyte differentiation in embryonic stem (ES) 
cells and in chick, Xenopus, and zebrafish embryos12-16. Thus, these results collectively 
suggest that IGFBP-4 promotes cardiogenesis by antagonizing Wnt/?-catenin pathway 
through direct interactions with Frizzled and LRP5/6. 
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Next we investigated the role of endogenous IGFBP-4 in P19CL6 cell differentiation 
into cardiomyocytes. RT-PCR analysis revealed that the expression of IGFBP-4 was 
upregulated during DMSO-induced P19CL6 cell differentiation (Fig. 3a). Expression of 
IGFBP-3 and –5 was also upregulated in the early and the late phase of differentiation, 
respectively. Expression of IGFBP-2 was not altered, and that of IGFBP-1 or –6 was not 
detected. When IGFBP-4 was knocked down by two different small interfering RNA 
(siRNA) ?constructs, DMSO-induced cardiomyocyte differentiation was inhibited in both 
cases (Fig. 3b). In contrast, knockdown of IGFBP-3 or IGFBP-5 did not inhibit DMSO-
induced cardiomyocyte differentiation (Fig. 3b, right panel). Treatment with an anti-
IGFBP-4 neutralizing antibody also blocked DMSO-induced cardiomyocyte differentiation 
(Fig. 3c). Thus, secretion of endogenous IGFBP-4 is required for cardiomyocyte 
differentiation of P19CL6 cells. IGFBP-4 immunostaining revealed that cardiac myocytes 
were surrounded by the IGFBP-4-positive cells, suggesting that a paracrine effect of 
IGFBP-4 on cardiomyocyte differentiation is predominant (Fig. 3d). Essentially the same 
results were obtained in ES cells (Supplementary Fig. S3d-g). To investigate whether 
IGFBP-4 promotes cardiomyocyte differentiation of P19CL6 cells via inhibition of 
canonical Wnt pathway, we expressed dominant-negative LRP6 (LRP6N) in P19CL6 cells. 
Expression of LRP6N enhanced cardiomyocyte differentiation of P19CL6 cells, and 
reversed the inhibitory effect of IGFBP-4 knockdown on cardiomyogenesis (Fig. 3e). These 
observations suggest that endogenous IGFBP-4 is required for cardiomyocyte 
differentiation of P19CL6 cells and ES cells, and that the cardiogenic effect of IGFBP-4 is 
mediated by its inhibitory effect on Wnt/?-catenin signaling. 
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The role of endogenous IGFBP-4 in cardiac development in vivo was also examined 
using Xenopus embryos. Whole mount in situ hybridization analysis revealed that strong 
expression of XIGFBP-4 was detected at stage 38 in the anterior part of the liver adjacent to 
the heart (Fig. 4a). Knockdown of XIGFBP-4 by two different morpholino (MO) constructs 
resulted in cardiac defects, with more than 70% of the embryos having small or no heart 
(Fig. 4b). The specificity of MO was confirmed by the observation that co-injection of MO-
resistant XIGFBP-4 cDNA rescued the MO-induced cardiac defects (Fig. 4b, 
Supplementary Fig. S4c). Importantly, co-expression of IGF binding-defective XIGFBP-4 
mutant (XIGFBP-4-H74P) or dominant-negative LRP6 (LRP6?) also rescued the cardiac 
defects induced by XIGFBP-4 knockdown (Fig. 4b), whereas overexpression of Xwnt8 in 
the heart forming region resulted in cardiac defects similar to those induced by XIGFBP-4 
knockdown (Supplementary Fig. S4d-f), supporting the notion that the cardiogenic effect of 
IGFBP-4 is independent of IGFs but is mediated by inhibition of Wnt/?-catenin pathway. 
Temporal profile of cardiac defects induced by XIGFBP-4 knockdown was also examined 
by cardiac Troponin I (cTnI) in situ hybridization (Fig. 4c). At stage 34, morphology of the 
heart was comparable between control embryos and MO-injected embryos. However, at 
stage 38, when XIGFBP-4 starts to be expressed in the anterior part of the liver, the 
expression of cTnI was markedly attenuated in MO-injected embryos, and expression of 
cTnI was diminished and no heart-like structure was observed at stage 42. Thus, the heart is 
initially formed but subsequent growth of the heart is perturbed in the absence of XIGFBP-
4, suggesting that IGFBP-4 promotes cardiogenesis by maintaining the proliferation and/or 
survival of embryonic cardiomyocytes. 
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It has been shown that canonical Wnt signals inhibit cardiogenesis in chick and frog 
embryos, and that Wnt antagonists such as Dkk1 and Crescent secreted from anterior 
endoderm or organizer region counteract the Wnt-mediated inhibitory signals and induce 
cardiogenesis in the anterior lateral mesoderm13-15. However, IGFBP-4-mediated Wnt 
inhibition is required at later stages of development, when the heart is already formed at the 
ventral portion and starts to grow and remodel to maintain embryonic circulation. It has 
been shown that Wnt/?-catenin signaling has time-dependent effects on cardiogenesis in ES 
cells: canonical Wnt signaling in the early phase of ES cell differentiation promotes 
cardiomyogenesis whereas it inhibits cardiomyocyte differentiation in the late phase12,16,17. 
Consistent with this notion, IGFBP-4 promoted cardiomyocyte differentiation of ES cells 
only when IGFBP-4 was applied in the late phase after embryoid body formation 
(Supplementary Fig. S3a-c). Similar time-dependent effects of Wnt/?-catenin signaling on 
cardiogenesis has been shown in zebrafish embryos16. Moreover, several recent reports 
suggest that Wnt/?-catenin signaling is a positive regulator of cardiac progenitor cell 
proliferation in the secondary heart field18-22. It therefore appears that canonical Wnt 
signaling has divergent effects on cardiogenesis at multiple stages of development: 
canonical Wnt signaling (i) promotes cardiogenesis at the time of gastrulation or mesoderm 
specification, (ii) inhibits cardiogenesis at the time when cardiac mesoderm is specified in 
the anterior lateral mesoderm, (iii) promotes the expansion of cardiac progenitors in the 
secondary heart field, and (iv) inhibits cardiogenesis at later stages when the embryonic 
heart is growing. It is interesting to note that IGFBP-4 is predominantly expressed in the 
liver. Mouse IGFBP-4 is also strongly expressed in the tissues adjacent to the heart such as 
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pharyngeal arches and liver bud at E9.5 (Supplementary Fig. S3h). These observations and 
the results of IGFBP-4 immunostaining in P19CL6 cells and ES cells suggest that IGFBP-4 
promotes cardiogenesis in a paracrine fashion. Together with a previous report showing 
that cardiac mesoderm secretes FGFs and induces liver progenitors in the ventral 
endoderm23, these observations suggest that there exist reciprocal paracrine signals between 
the heart and the liver that coordinately promote the development of each other.  
IGFBPs are composed of 6 members, IGFBP-1 to -6. Reporter gene assays and ?-
catenin stabilization assays revealed that IGFBP-4 was the most potent canonical Wnt 
inhibitor, and IGFBP-1, -2, and -6 also exhibited modest activities of Wnt inhibition, 
whereas IGFBP-3 and -5 had no such activity (Supplementary Fig. S5a-c). Consistent with 
this, IP/Western analyses demonstrated that IGFBP-1, -2, -4, and -6 but not IGFBP-3 or -5 
interacted with LRP6 or Frz8CRD (Supplementary Fig. S5d,e). Thus, lack of cardiac 
phenotypes in IGFBP-4 null mice or IGFBP-3/4/5 triple knockout mice24 may be due to 
genetic redundancies between IGFBP-4 and other IGFBPs such as IGFBP-1, -2 and/or -6. 
The identification of IGFBP-4 as an inhibitor of Wnt/?-catenin signaling may also have 
some implications in cancer biology25. It was shown that treatment with IGFBP-4 reduces 
cell proliferation in some cancer cell lines in vitro, and that overexpression of IGFBP-4 
attenuates the growth of prostate cancer in vivo. Decreased serum levels of IGFBP-4 are 
associated with the risk of breast cancer. Since activation of Wnt signaling is implicated in 
several forms of malignant tumors26,27, it is possible that the inhibitory effect of IGFBP-4 on 
cell proliferation is mediated in part by the inhibition of canonical Wnt signaling. 
 - 11 - 
Methods Summary 
Cell Culture 
P19CL6 cells and ES cells were cultured and induced to differentiate into cardiomyocytes 
essentially as described7,12. P19CL6 cells (2000 cells/35 mm dish) were treated with various 
conditioned media for screening of their cardiogenic activities. For siRNA-mediated 
knockdown, pSIREN-RetroQ vectors (Clontech) ligated with double-strand 
oligonucleotides were transfected into P19CL6 cells or ES cells, and puromycin-resistant 
clones were selected.  
IP/Western analyses and binding assays 
Conditioned media for IP/Western analyses were produced using 293 cells. Binding 
reactions were performed at 4ºC overnight. 125I-labeling of IGFBP-4 and Wnt3A was 
performed using IODO-BEADS Iodination Reagent (Pierce). A liquid-phase binding assay 
was performed essentially as described28. 
Xenopus experiments 
Axis duplication assays, animal cap assays, and in situ hybridization analyses in Xenopus 
were done essentially as described29. Electroporation of mRNA was done at stage 28 
essentially as described30.  
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Methods 
Plasmids and Reagents 
cDNA clones for mouse IGFBPs and Xenopus IGFBP-4 were purchased from Open 
Biosystems. XIGFBP-4-H74P mutant was generated by QuickChange Site-Directed 
Mutagenesis kit (Stratagene). His-tagged human wild type IGFBP-4 and mutant IGFBP-4-
H74P (vectors provided by X. Qin)9 were produced and purified using HisTrap HP Kit 
(Amersham). Full-length Frz8, Frz8CRD, and LRP6N were provided by X. He31,32. Full 
length LRP6, membrane-bound forms of LRP6 deletion mutants, and Dkk1 were from C. 
Niehrs33. pXwnt8 and pCSKA-Xwnt8 were from J. Christian34,35. pCS2-?-catenin was from 
D. Kimelman36. ?MHC-GFP was from B. Fleischmann37. BRE-luc was from P ten Dijke38. 
pCGN-Dvl-1 was previously described39. Soluble forms of LRP6 deletion mutants and 
probes for in situ hybridization analysis (Nkx2.5, cTnI, and Hex) were generated by PCR. 
IGFBP-4, Wnt3A, IGF-I, IGF-II, and BMP2 were from R&D. Neutralizing antibodies were 
from R&D (anti-IGFBP-4), Sigma (anti-IGF-I and anti-IGF-II), and Oncogene (anti-type-I 
IGF receptor). The antibodies used for IP, Western blotting, and immunostaining were from 
Invitrogen (anti-Myc, anti-V5), Santa Cruz (anti-cTnT, anti-IGFBP-4, anti-topoisomerase I 
(TOPO-I)), Sigma (anti-?-actin, anti-?-catenin, anti-FLAG (M2)), and Developmental 
Studies Hybridoma Bank (anti-sarcomeric myosin heavy chain (MF20)).  
Cell Culture Experiments 
P19CL6 cells and ES cells were cultured and induced to differentiate into cardiomyocytes 
essentially as described7,12. P19CL6 cells (2000 cells/35 mm dish) were treated with various 
conditioned media for screening of their cardiogenic activities. P19CL6 cells or ES cells 
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stably transfected with ?MHC promoter driven-green fluorescence protein (GFP) were 
generated by transfection of ?MHC-GFP plasmid into P19CL6 cells or ht7 ES cells 
followed by G418 selection. Luciferase reporter gene assays, Western blot analyses, 
immunostaining, and RT-PCR were performed as described12. Reporter gene assays were 
repeated at least three times. PCR primers and PCR conditions are listed in Supplementary 
Table S1. For siRNA-mediated knockdown, siRNAs were expressed using pSIREN-RetroQ 
vector (Clontech). Oligonucleotide sequences used are listed in Supplementary Table S2. 
pSIREN-RetroQ vectors ligated with double-strand oligonucleotides were transfected into 
P19CL6 cells or ES cells, and puromycin-resistant clones were isolated and expanded. For 
?-catenin stabilization assays, nuclear extracts of L cells were prepared using NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Pierce). Data are shown as mean ± standard 
deviation.  
IP/Western analyses and binding assays 
Conditioned media for IP/Western analyses containing full length or various deletion 
mutants of IGFBPs, LRP6, Frz8CRD, and Dkk1 were produced using 293 cells. Binding 
reactions were performed at 4ºC overnight. IP was performed using Protein G Sepharose 4 
Fast Flow (Amersham). 125I-labeling of IGFBP-4 and Wnt3A was performed using IODO-
BEADS Iodination Reagent (Pierce). A liquid-phase binding assay was performed 
essentially as described28. In brief, conditioned media containing LRP6N-Myc or 
Frz8CRD-Myc were mixed with various concentrations of 125I-labeled IGFBP-4, and 
incubated at 4ºC overnight. LRP6N-Myc or Frz8CRD-Myc was immunoprecipitated, and 
radioactivity of bound IGFBP-4 was measured after extensive washing of the Protein G 
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sepharose beads. For a competitive binding assay, conditioned media containing LRP6N-
Myc or Frz8CRD-Myc were mixed with 125I-labeled Wnt3A and cold IGFBP-4, and 
incubated at 4ºC overnight. LRP6N-Myc or Frz8CRD-Myc was then immunoprecipitated, 
and radioactivity of bound Wnt3A was measured. 
Xenopus experiments and mouse in situ hybridization analysis 
Axis duplication assays, animal cap assays, and in situ hybridization analyses in Xenopus 
were done essentially as described29. Two independent cDNAs for XIGFBP-4, presumably 
resulting from pseudotetraploid genomes, were identified by 5’ RACE (Supplementary Fig. 
S4a). Two different MOs that target both of these two IGFBP-4 transcripts were designed 
(Gene Tools) (Supplementary Fig. S4a and Supplementary Table S2). MO-sensitive 
XIGFBP-4 cDNA that includes 41bp 5’-UTR was generated by PCR. MO-resistant 
XIGFBP-4 cDNA (wild type and H74P mutant) was generated by introducing five silent 
mutations in the MO1 target sequence and excluding the 5’-UTR (Supplementary Fig. S4a). 
To determine the specificity of MOs, MO-sensitive or MO-resistant XIGFBP-4-Myc 
mRNA was injected into Xenopus embryos with or without MOs, and protein/mRNA 
expression was analyzed. PCR primers and PCR conditions are listed in Supplementary 
Table S1. MOs and plasmid DNAs were injected at the 8-cell stage into the dorsal region of 
two dorsal-vegetal blastomeres fated to be heart and liver anlage. Electroporation of mRNA 
was done essentially as described30. Injection of mRNA (5 ng in 5 nl solution) into the 
vicinity of heart anlage and application of electric pulses was performed at stage 28. Whole 
mount in situ hybridization analysis of murine IGFBP-4 was performed as described40.
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Figure Legends 
Figure 1. IGFBP-4 promotes cardiomyocyte differentiation in an IGF-independent 
manner.  
a, Culture media conditioned by OP9 cells but not COS7 cells induced cardiomyocyte 
differentiation of P19CL6 cells as assessed by MF20-positive area, cardiac marker gene 
expression, and cTnT protein expression. Scale bar=100 µm. b, Treatment with IGFBP-4 (1 
µg/ml) induced cardiomyocyte differentiation of P19CL6 cells in the absence of DMSO. c, 
Treatment with a neutralizing antibody against IGFBP-4 (?BP4, 40 µg/ml) attenuated 
cardiomyocyte differentiation of P19CL6 cells induced by OP9-conditioned media. d, 
Treatment with neutralizing antibodies against IGF-I and IGF-II (?IGFs, 5 µg/ml each) had 
no effect on IGFBP-4-induced cardiomyocyte differentiation of P19CL6 cells. e, Mutant 
IGFBP-4 (IGFBP-4-H74P) that is incapable of binding to IGFs retained cardiomyogenic 
activity. f, IGFs (100 ng/ml each) attenuated wild type IGFBP-4-induced but not mutant 
IGFBP-4-H74P-induced cardiomyocyte differentiation of P19CL6 cells.  
Figure 2. IGFBP-4 inhibits Wnt/?-catenin signaling through direct interactions with 
Wnt receptors.  
a, IGFBP-4 attenuated ?-catenin-dependent transcription in P19CL6 cells. P19CL6 cells 
were transfected with TOPFLASH reporter gene and expression vectors for LRP6 or Frz8, 
treated with Wnt3A or Wnt3A plus IGFBP-4, and luciferase activities were measured. b, 
XIGFBP-4 inhibited Xwnt8-induced secondary axis formation in Xenopus embryos (N=20 
for each group). c, IGFBP-4 inhibited LRP6-induced secondary axis formation in Xenopus 
embryos (N=30 for each group). d,e, IGFBP-4 directly interacted with LRP6N (d) and 
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Frz8CRD (e). f, A binding assay between 125I-labeled IGFBP-4 and LRP6N. Inset is a 
scatchard plot showing two binding sites with different binding affinities. g, A binding 
assay between 125I-labeled IGFBP-4 and Frz8CRD. Inset is a scatchard plot showing a 
single binding site. h,i, IGFBP-4 inhibited Wnt3A binding to LRP6N (h) or Frz8CRD (i). 
125I-labeled Wnt3A binding to LRP6N or Frz8CRD was assessed in the presence of 
increasing amounts of IGFBP-4.  
Figure 3. IGFBP-4 is required for cardiomyocyte differentiation of P19CL6 cells.  
a, Expression analysis of IGFBP family members by RT-PCR during DMSO-induced 
cardiomyocyte differentiation of P19CL6 cells (from day 0 to day 8). b, Knockdown of 
IGFBP-4 in P19CL6 cells attenuated cardiac marker expression in response to DMSO 
treatment (left). BP4-1 and BP4-2 represent two different siRNAs for IGFBP-4. 
Knockdown of IGFBP-3 or IGFBP-5 had no effect on cTnT expression in response to 
DMSO treatment (right). c, Treatment with a neutralizing antibody against IGFBP-4 (?BP4, 
40 µg/ml) attenuated DMSO-induced cardiomyocyte differentiation of P19CL6 cells. d, 
IGFBP-4 immunostaining during DMSO-induced differentiation of P19CL6 cells stably 
transfected with ?MHC-GFP reporter gene. Upper left, IGFBP-4 staining (red); upper right, 
GFP expression representing differentiated cardiomyocytes; lower left, nuclear staining by 
DAPI; lower right, a merged picture. Scale bar=100 µm. e, Attenuated cardiomyocyte 
differentiation of P19CL6 cells by IGFBP-4 knockdown was rescued by inhibiting Wnt/?-
catenin signaling. Control and IGFBP-4-knocked-down P19CL6 cells were transfected with 
an expression vector for GFP or LRP6N (a dominant-negative form of LRP6), and induced 
to differentiate into cardiomyocytes by DMSO treatment. LRP6N overexpression rescued 
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the attenuated cardiomyocyte differentiation induced by IGFBP-4 knockdown as assessed 
by MF20-positive area (left panel), cardiac marker gene expression, and cTnT protein 
expression (right panel). 
Figure 4. IGFBP-4 is required for the maturation of the heart in Xenopus embryos.  
a, In situ hybridization analysis of Nkx2.5 (an early cardiac marker), cTnI (a mature cardiac 
marker), Hex (a liver marker), and XIGFBP-4 mRNA expression at stage 34, 38, and 42. b, 
Knockdown of XIGFBP-4 by two different morpholinos (MO1 and MO2) resulted in 
severe cardiac defects as assessed by cTnI in situ hybridization at stage 42 (left). These 
cardiac defects were rescued by co-injection of MO-resistant wild type XIGFBP-4, mutant 
XIGFBP-4-H74P, and LRP6N (N=30 for each group). c, Temporal profile of cardiac 
defects induced by XIGFBP-4 knockdown. Morphology of the heart as assessed by cTnI in 
situ hybridization was almost normal at stage 34 but was severely perturbed at stage 38 and 
42. Right column shows sections of control and MO-injected embryos. Arrow indicates the 
heart in control embryos. No heart-like structure was observed in MO-injected embryos. 
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Supplementary Figure Legends 
Supplementary Figure S1. Inhibition of canonical Wnt pathway by IGFBP-4.  
a, IGFBP-4 did not alter FOPFLASH activity. FOPFLASH activity was measured in 
P19CL6 cells as a control experiment shown in Fig. 2a. b, IGFBP-4 did not alter BMP-
induced activation of BRE-luc reporter gene. BMP-responsive BRE-luc was activated by 
BMP2 in a dose-dependent manner (left), and this activation was not altered by IGFBP-4 
(right). c, Animal cap assays. RNA was injected into the animal pole of two-cell embryos, 
and the animal caps were dissected at stage 8.5. Expression of Wnt target genes (Siamois 
and Xnr-3) induced by LRP6 but not by ?-catenin was attenuated by XIGFBP-4. d,e, 
TOPFLASH reporter gene assays. IGFBP-4 inhibited canonical Wnt signaling activated by 
Wnt3A (d, left) or LRP6 (d, right). However, IGFBP-4 did not inhibit canonical Wnt 
pathway activated by ?-catenin, Dishevelled-1 (Dvl-1) (e, left), or GSK3 inhibitor LiCl (e, 
right). TOPFLASH reporter gene assays shown in b,d,e were performed in 293 cells. 
Supplementary Figure S2. Interaction of IGFBP-4 with Frz8/LRP6.  
a, A binding assay between 125I-labeled Wnt3A and Frz8CRD in the absence or the 
presence of different doses of IGFBP-4 (rectangles, no IGFBP-4; circles, IGFBP-4 (50nM); 
triangles, IGFBP-4 (100nM)). Inset is a Lineweaver-Burk plot showing that IGFBP-4 is a 
competitive inhibitor of Wnt3A binding to Frz8CRD. b, Schematic illustration of LRP6 
deletion mutants used in this study. All deletion mutants are soluble forms. SP, signal 
peptide; ?-pro, ?-propeller domain; EGF, EGF-like domain; LDLR, LDL receptor typeA 
repeats; TM, transmembrane domain. c-e, IGFBP-4 interacts with multiple domains of 
LRP6. As assessed by IP/Western analyses, IGFBP-4 interacted with LRP6N and E1-4 
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mutants of LRP6 (c), E1-2/L, E3-4/L, and L mutants of LRP6 (d), and E1-2, E3-4, and L 
mutants of LRP6 (e). As a control, Dkk1 interacted predominantly with E3-4 mutant of 
LRP6 (e). NS represents non-specific bands. f, Carboxy-terminal thyroglobulin domain of 
IGFBP-4 is required for interaction with Frz8/LRP6. Deletion mutants of IGFBP-4 used are 
shown on the left panel. IGF and TG represent an IGF-binding domain and a thyroglobulin 
domain, respectively. Full length (FL) and ?N mutant of IGFBP-4 interacted with 
Frz8/LRP6 but ?C mutant did not. 
Supplementary Figure S3. IGFBP-4 promotes cardiomyocyte differentiation of ES 
cells in a paracrine fashion.  
a-c, ES cells stably transfected with ?MHC-GFP reporter gene were induced to 
differentiate into cardiomyocytes by a hanging drop method. IGFBP-4 (1 µg/ml) 
suppressed cardiomyocyte differentiation of ES cells when applied from day 0 to day 3 
(D0-3), whereas it enhanced cardiogenesis when applied from day 3 to day 5 (D3-5). The 
extent of cardiomyocyte differentiation was assessed by GFP-positive area (a,b), cardiac 
marker gene expression (c, upper panel), and cTnT protein expression (c, lower panel). 
Scale bar=200 µm. d, Expression analysis of IGFBP family members by RT-PCR during 
cardiomyocyte differentiation of ES cells. e, Knockdown of IGFBP-4 in ES cells attenuated 
cardiac marker gene expression (left) and cardiomyocyte differentiation as assessed by 
GFP-positive area and cTnT expression (right). BP4-1 and BP4-2 represent two different 
siRNAs for IGFBP-4. Knockdown of IGFBP-3 or IGFBP-5 had no effect on cardiomyocyte 
differentiation (right). f, Treatment with a neutralizing antibody against IGFBP-4 (?BP4, 
40 µg/ml) attenuated cardiomyocyte differentiation of ES cells as assessed by GFP-positive 
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area, cardiac marker gene expression, and cTnT protein expression. g, IGFBP-4 
immunostaining during cardiomyocyte differentiation of ES cells stably transfected with 
?MHC-GFP reporter gene. Upper left, IGFBP-4 staining (red); upper right, GFP expression 
representing differentiated cardiomyocytes; lower left, nuclear staining by DAPI; lower 
right, a merged picture. Scale bar=100 µm. h, In situ hybridization analysis of murine 
IGFBP-4 at E9.5. Strong signals were detected in pharyngeal arches, liver bud, and limb 
buds. S, sense probe; AS, antisense probe. 
Supplementary Figure S4. Knockdown of XIGFBP-4 or activation of Wnt pathway 
disrupts normal cardiac development in Xenopus embyros.  
a, Sequences of two XIGFBP-4 alleles and positions of MO target sequences are indicated. 
MO-sensitive and MO-resistant XIGFBP-4 cDNA sequences are also shown. Initiation 
codon is indicated by red, and mismatches introduced to generate MO-resistant XIGFBP-4 
cDNA are shown by underlines. MO-s and MO-r represent MO-sensitive and MO-resistant 
XIGFBP-4 cDNA, respectively. b, Verification of MO activity and specificity. MO-
sensitive and MO-resistant XIGFBP-4-Myc mRNA was injected into Xenopus embryos. 
Expressions of XIGFBP-4-Myc protein translated from MO-sensitive mRNA were 
downregulated by co-injection of MO1 or MO2, whereas those of XIGFBP-4-Myc protein 
translated from MO-resistant mRNA were not. RT-PCR analysis showed comparable 
amounts of injected mRNA. ODC represents ornithine decarboxylase and served as RT-
PCR controls. c, Specificities of cardiac phenotypes induced by XIGFBP-4 MOs. Cardiac 
defects induced by XIGFBP-4 MO1 or MO2 were rescued by co-injection of MO-resistant 
XIGFBP-4 cDNA (N=30 for each group). d, Activation of Wnt pathway disrupts normal 
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heart development. For Wnt activation in the heart forming region, plasmid DNA encoding 
Xwnt8 under the control of cytoskeletal actin promoter (pCSKA-Xwnt8) was injected at the 
8-cell stage into the dorsal region of two dorsal-vegetal blastomeres fated to be heart and 
liver anlage. When compared to control embryos (upper panel), Wnt activation by pCSKA-
Xwnt8 injection resulted in the attenuation of heart size at stage 42 (lower panel). e, 
Activation of Wnt pathway in the late phase of embryogenesis is sufficient to perturb 
cardiogenesis. Xwnt8 mRNA was introduced into the vicinity of heart anlage by 
electroporation at stage 28. GFP mRNA was co-injected to evaluate the efficiency of 
electroporation. At stage 34, GFP expression was observed at the heart forming area (upper 
panel, anterior to the left and dorsal is up). When compared to control embryos injected 
with GFP mRNA alone (middle panel), embryos injected with Xwnt8 and GFP mRNA 
exhibited abnormal heart morphogenesis at stage 42 (lower panel). f, A quantitative 
analysis of the effects of Wnt activation on cardiac development.  
Supplementary Figure S5. Wnt inhibition by IGFBPs. 
a, ?-catenin stabilization assays in L cells. Treatment with Wnt3A induced a robust 
increase in the amount of nuclear ?-catenin, which was reversed by IGFBP-4. b,c, ?-
catenin stabilization assays (b) and TOPFLASH reporter gene assays (c) in the absence or 
the presence of IGFBPs. IGFBPs were added at the concentration of 500ng/ml. d,e, 
IP/Western analyses to examine the physical interactions between IGFBPs and LRP6 (d) or 
Frz8CRD (e). IGFBP-1, -2, -4, and -6 interacted with LRP6/Frz8CRD, whereas IGFBP-3 
and -5 did not.
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Supplementary Table S1. PCR primers and PCR conditions 
Gene Primers PCR product Annealing
(bp) (C˚)
?MHC 5'-GGAAGAGTGAGCGGCCATCAAGG-3' 302 65
5'-CTGCTGGAGAGGTTATTCCTCG-3'
Nkx2.5 5'-CAGTGGAGCTGGACAAAGCC-3' 216 55
5'-TAGCGACGGTTCTGGAATTT-3'
GATA-4 5'-CTGTCATCTCACTATGGGCA-3' 275 60
5'-CCAAGTCCGAGCAGGAATTT-3'
?-actin 5'-GGACCTGGCTGGCCGGGACC-3' 583 60
5'-GCGGTGCACGATGGAGGGGC-3' 
IGFBP-1 5'-CCAGGGATCCAGCTGCCGTGCG-3' 259 60
5'-GGCGTTCCACAGGATGGGCTG-3'
IGFBP-2 5'-CAACTGTGACAAGCATGGCCG-3' 176 60
5'-CACCAGTCTCCTGCTGCTCGT-3'
IGFBP-3 5'-GACACCCAGAACTTCTCCTCC-3' 220 60
5'-CATACTTGTCCACACACCAGC-3'
IGFBP-4 5'-CGTCCTGTGCCCCAGGGTTCCT-3' 200 60
5'-GAAGCTTCACCCCTGTCTTCCG-3'
IGFBP-5 5'-GTTTGCCTCAACGAAAAGAGCT-3' 393 60
5'-CTGCTTTCTCTTGTAGAATCCTT-3'
IGFBP-6 5'-CCCCGAGAGAACGAAGAGACG-3' 351 60
5'-CTGCGAGGAACGACACTGCTG-3'
XIGFBP-4 (MO-s) 5'-CAAACTCATTCATCTCCAGCCC-3' 808 55
5'-TTCCTTTCCCCTCTCAGATGCC-3'
XIGFBP-4 (MO-r) 5'-ATGTCAGGTTACTGTCATCCTGCCC-3' 767 55
5'-TTCCTTTCCCCTCTCAGATGCC-3'
Siamois 5 -TACCGCACTGACTCTGCAAG-3 192 62
5 -CTGAGGCTCCTGTGGAATTC-3
Xnr-3 5 -CTTCTGCACTAGATTCTG-3 281 58
5 -CAGCTTCTGGCCAAGACT-3
ODC 5'-GTCAATGATGGAGTGTATGGATC-3' 386 55
5'-TCCAATCCGCTCTCCTGAGCAC-3'
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Supplementary Table S2. Oligonucleotide sequences for siRNAs and morpholinos 
 
 
 
Gene Oligonucleotide Sequences
mIGFBP-3 AATCCTAGATGAAGTGTTA
mIGFBP-4-1 GAGCCAGGCTGCGGTTGTT
mIGFBP-4-2 GCAAGTGCTGGTGTGTGGA
mIGFBP-5 AAGGCCTCCAAGCTAATTA
XIGFBP-4-MO1 GCAGGGTGGCAATATCCAGACATGA
XIGFBP-4-MO2 CTTGCTGGGCTGGAGATGAATGAGT
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